| Time to fall asleep with delayed sleep phase | With confirmed delayed sleep phase and the same sleep schedule, 0.5 mg melatonin reduced time to fall asleep by 11.9 minutes versus placebo.Mean difference −11.9 minutes (95% CI −19.54…−4.39). | 3/4 ModerateConfidence is moderate: in a blinded study, melatonin together with a sleep schedule identical for both groups reduced time to fall asleep on average across treatment nights. The interval allows both a small and a more noticeable reduction; the result does not describe the final week separately. | 11 trialEfficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial ↗ | 116 randomised participants with confirmed delayed phase | - Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial ↗
|
|---|
| Clock time of sleep onset | With the same schedule, sleep onset occurred 34 minutes earlier by the clock than with placebo.Mean difference −34 minutes (95% CI −60…−8). | 3/4 ModerateConfidence is moderate: in a blinded study, participants taking melatonin fell asleep earlier by the clock on average, but the possible size of the shift remains wide. Both groups followed the same sleep schedule; the result does not refer separately to the final week. | 11 trialEfficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial ↗ | 116 randomised participants with confirmed delayed phase | - Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial ↗
|
|---|
| Falling asleep with insomnia at ages 65–80 | In 281 participants aged 65–80 with insomnia, 2 mg prolonged-release melatonin reduced diary-reported time to fall asleep by 15.6 minutes over three weeks versus placebo.Mean difference −15.6 minutes (95% CI −25.3…−6.0). | 3/4 ModerateConfidence is moderate: in a prespecified age subgroup of a blinded study, time to fall asleep decreased, but the confidence interval allows different sizes of improvement. The data relate to three weeks and participants aged 65–80. | 11 trialNightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety ↗ | 281 randomised participants aged 65–80 with primary insomnia, subgroup of 791 | - Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety ↗
|
|---|
| Days with migraine pain | In adults with migraine, 3 mg melatonin at night over 12 weeks reduced headache days by 1.6 days per month more than placebo.Difference in changes −1.6 days per month (95% CI −2.4…−0.9); 7.3→4.6 versus 7.3→6.2 days per month. | 3/4 ModerateConfidence is moderate: in the study melatonin reduced the number of migraine days, but some data were lost, and missing days were counted as migraine-free in the main analysis. | 11 trialRandomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention ↗ | 119 analysed adults with migraine in the compared groups; a third amitriptyline group was separate | - Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention ↗
|
|---|
| Number of migraine attacks | In another eight-week trial, 2 mg prolonged-release melatonin did not clearly reduce migraine attacks versus placebo (p=0.497).2.8±1.6 attacks per month while taking melatonin; between-group p=0.497. | 3/4 ModerateConfidence is moderate: in a blinded crossover study, attack frequency with melatonin did not differ convincingly from placebo, but the sample was small and the exact interval for the difference is unavailable. Absence of a significant difference does not prove equal effects. | 11 trialProphylaxis of migraine with melatonin: a randomized controlled trial ↗ | 48 randomised adults with migraine, 46 completed | - Prophylaxis of migraine with melatonin: a randomized controlled trial ↗
|
|---|
| Early morning wakefulness | In 61 middle-aged participants with primary insomnia, 3 mg immediate-release melatonin over four weeks reduced early morning wakefulness by 30.6 minutes versus placebo.Mean difference −30.63 minutes (95% CI −53.92…−7.34). | Not assessedThe certainty of the result cannot yet be assessed: the available abstract reports a difference but does not explain how it was calculated or confirm the composition of the final analysis. | 11 trialEfficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial ↗ | 61 in the final analysis (29 melatonin, 32 placebo; 97 randomised) | - Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial ↗
|
|---|
| Other polysomnographic sleep measures | In the same trial, no clear difference was found in latency, total duration, wakefulness after sleep onset or sleep efficiency.Time to fall asleep +53.89 minutes (CI −41.27…149.05); total sleep time +20.90 minutes (CI −12.67…54.47); wakefulness after sleep onset −20.84 minutes (CI −46.14…4.46); sleep efficiency +3.19 percentage points (CI −3.23…9.60). | Not assessedThe certainty of the result for four sleep measures cannot yet be assessed: the available abstract does not contain the corresponding numbers and does not allow their calculation to be checked. | 11 trialEfficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial ↗ | 61 in the final analysis (29/32) | - Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial ↗
|
|---|
| Falling asleep in children and adolescents | In children and adolescents aged 5–20 with idiopathic chronic insomnia, diary-reported time to fall asleep was 18 minutes shorter on average.Mean difference −18.03 minutes (95% CI −26.61…−9.44). | 3/4 ModerateConfidence is moderate: according to diaries in several small studies, children and adolescents fell asleep earlier, but blinding and allocation methods were inadequately described in some studies. Doses and durations varied, and the conclusion relates to short follow-up. | 33 trials in the reviewUse of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗ | 142 children and adolescents aged 5–20 | - Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗
|
|---|
| Sleep duration in children and adolescents | In four trials in the same group, diary-reported sleep duration was 30 minutes longer on average versus placebo.Mean difference +30.33 minutes (95% CI +18.96…+41.70). | 3/4 ModerateConfidence is moderate: according to diaries in several small studies, sleep duration increased, but allocation and blinding methods were insufficiently clear in some studies. This result does not establish long-term benefit or an effect on daytime well-being. | 44 trials in the reviewUse of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗ | 184 children and adolescents aged 5–20 | - Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗
|
|---|
| Cycling time and power | In ten trained men, 5 mg melatonin 15 minutes before a 32.2 km cycling race did not change race time or average power versus placebo.Time 64.94±5.95 versus 65.26±6.85 minutes, p=0.682; power 190.4±40.4 versus 190.0±45.7 W, p=0.927. | 3/4 ModerateConfidence is moderate: in ten trained men, ride time and average power did not differ convincingly from placebo. The study was small, and absence of a significant difference does not rule out an effect on either measure. | 11 trialConsumption of a 5-mg Melatonin Supplement Does Not Affect 32.2-km Cycling Time Trial Performance ↗ | 10 trained male cyclists | - Consumption of a 5-mg Melatonin Supplement Does Not Affect 32.2-km Cycling Time Trial Performance ↗
|
|---|
| Sleep efficiency | In 59 adults aged 30–60 with poor sleep, over 28 days sleep efficiency changed by +3.49 percentage points with 2 mg prolonged-release melatonin versus −6.30 with placebo.Change +3.49 versus −6.30 percentage points, p=0.001. | 3/4 ModerateConfidence is moderate: in a small blinded study, sleep efficiency changed in favour of melatonin, but part of the difference was related to worsening with placebo. The exact size of the effect remains uncertain. | 11 trialEfficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled) | - Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Sleep duration | In the same trial, total sleep time changed by +23.83 minutes versus −39.25 minutes with placebo.Change +23.83 versus −39.25 minutes, p=0.001. | 3/4 ModerateConfidence is moderate: in a small blinded study, sleep duration changed in favour of melatonin; it decreased with placebo. The exact size of the benefit is difficult to assess. | 11 trialEfficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled) | - Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Time to fall asleep | In the same trial, time to fall asleep changed by −10.28 minutes versus +16.70 minutes with placebo.Change −10.28 versus +16.70 minutes, p=0.031. | 3/4 ModerateConfidence is moderate: in a small blinded study, time to fall asleep changed in favour of melatonin, but increased with placebo. The exact size of the difference remains uncertain. | 11 trialEfficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled) | - Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Wakefulness after sleep onset | In the same trial, wakefulness after sleep onset changed by −14.92 minutes versus +24.71 minutes with placebo.Change −14.92 versus +24.71 minutes, p=0.001. | 3/4 ModerateConfidence is moderate: in a small blinded study, time awake after sleep onset changed in favour of melatonin, but increased with placebo. The exact size of the difference remains uncertain. | 11 trialEfficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled) | - Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| PSQI sleep quality score | On day 28, the total PSQI sleep quality score changed by −5.61 points versus −0.65 points with placebo.Change −5.61 versus −0.65 PSQI points, p=0.001. | 3/4 ModerateConfidence is moderate: in a small blinded study, the sleep quality score improved more with melatonin, but a comparative confidence interval was not reported. The result concerns self-assessment after 28 days. | 11 trialEfficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled) | - Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|